Skip to main content
Home
Latest news
Browse topics
Cardiovascular disorders
Chronic kidney disease
Diabetes devices & technology
GLP-1 receptor agonists
Hyperglycemia
Hypoglycemia
Obesity, diet, & lifestyle interventions
SGLT2 inhibitors
Type 1 diabetes
Type 2 diabetes
Browse all topics
EN
EN
In focus
Novel clinical evidence in continuous glucose monitoring
Fasting for religion and health in people with diabetes
The challenge of type 2 diabetes in children
HFpEF & diabetes: Diagnosis and management in the wake of EMPEROR-Preserved
Addressing suicide risk in diabetes: Rates and risk factors, HCP fears, and practical advice
The SURPASS trials: Summarizing efficacy data on tirzepatide
Semaglutide for weight loss: STEP and SELECT trials: Results from the STEP and SELECT trials
Why psychosocial care matters
DiRECT: Type 2 diabetes remission through weight management
Congress coverage
EASD 58th Annual Meeting 2022
The American Diabetes Association 82nd Scientific Sessions
About us
Medicine Matters Diabetes
EXTENDED SEARCH
Log in

GLP-1 receptor agonists


Browse the latest news, expert commentary, and educational content on the GLP-1 receptor agonist medication class.


Initiating GLP-1 receptor agonists: Managing side effects

Specialist nurse Nicola Milne discusses the side effects that can arise in people with type 2 diabetes during initiation of GLP-1 receptor agonists, and how to best manage them.

Latest

06-05-2023 | Prediabetes | News

Caloric restriction outperforms liraglutide for weight loss in prediabetes

03-10-2023 | Primary care | News

COORDINATEd intervention boosts optimal prescribing in type 2 diabetes with ASCVD

02-08-2023 | Heart failure | News

Meta-analysis shows mixed picture for GLP-1 receptor agonists in heart failure

01-09-2023 | Semaglutide | News

FDA approves high-dose semaglutide for adolescents with obesity

12-01-2022 | Semaglutide | News

High-dose semaglutide reduces obesity-linked inflammatory marker

11-22-2022 | Dulaglutide | News

FDA clears dulaglutide for adolescents
more

The STEP and SELECT trials

Keep up with the news and expert comment on the STEP and SURMOUNT phase 3 trials of semaglutide 2.4 mg in people with obesity.

Browse the hub

The SURPASS trials

Click through for clinical trial updates and expert reaction to the SURPASS and SURMOUNT phase 3 trials of the novel dual-action medication tirzepatide in people with type 2 diabetes and/or obesity.

Browse the hub

Beyond glucose lowering | Cardioprotection

10-17-2017 | GLP-1 agonists | At a glance | Article

Round up of the GLP-1 receptor agonist CV outcome trials

medwireNews provides a brief overview of the published and ongoing glucagon-like peptide-1 receptor agonist cardiovascular outcomes trials.

07-02-2019 | Dulaglutide | Podcast | Article

REWIND, DECLARE, and high-risk diabetes patients

How will the findings of the REWIND trial and the DECLARE-TIMI 58 renal outcomes analysis affect treatment decisions for high-risk diabetes patients without overt cardiovascular disease? medwireNews asks Kamlesh Khunti.

01-30-2019 | Cardiovascular outcomes | Case study | Article

Cardiovascular risk reduction in type 2 diabetes

Pharmacological management of comorbid cardiovascular risk and type 2 diabetes is undergoing a paradigm shift. General practitioner Kevin Fernando puts recommendations from the ADA/EASD into practice in this patient case study.

Beyond glucose lowering | Novel formulations

04-29-2020 | Type 2 diabetes | Podcast | Article

Is oral semaglutide a game changer or nice-to-have for type 2 diabetes?

US primary care physician Neil Skolnik discusses the role of oral semaglutide in the care of people with type 2 diabetes and outlines key considerations for its use (12:26).

05-06-2020 | Type 2 diabetes | Editorial | Article

Oral semaglutide: A technical triumph, with caveats

Diabetologist and Editorial Board member John Wilding gives his opinion on the latest addition to the GLP-1RA class, oral semaglutide.

The clinical trials

10-14-2020 | Tirzepatide | At a glance | Article

A quick guide to the SURPASS and SURMOUNT trials
Phase 3 and 4 trials of tirzepatide in type 2 diabetes and obesity

Read our overview of the SURPASS trials of the dual GLP-1/GIP receptor agonist tirzepatide in people with type 2 diabetes, plus the SURMOUNT trials in people with obesity.

02-11-2021 | Semaglutide | At a glance | Article

A quick guide to the STEP trials

Read our round-up of the STEP phase 3 trials of semaglutide 2.4 mg in people with obesity, plus the SELECT cardiovascular outcomes trial.

07-03-2019 | Semaglutide | At a glance | Article

A quick guide to the PIONEER trials

medwireNews rounds up the ongoing, reported, and published trials from the PIONEER oral semaglutide program.

04-07-2017 | Semaglutide | At a glance | Article

A quick guide to the SUSTAIN trials

02-07-2022 | Dulaglutide | At a glance | Article

A quick guide to the AWARD trials

08-09-2022 | Lixisenatide | At a glance | Article

A quick guide to the GetGoal trials

08-09-2022 | Liraglutide (T2DM) | At a glance | Article

A quick guide to the LEAD trials

02-08-2022 | Exenatide | At a glance | Article

A quick guide to the DURATION trials

Stay informed with Medicine Matters

Get the latest developments in diabetes delivered straight to your inbox

Sign up for the e-alert today
Image Credits